TABLE 1

Firing rates of VTA neurons: effects of inhibitors and quinpirole

Figures	Change by inhibitors	Pre-quinpirole or DA baseline FR (Hz)	Percentage change by DA or quinpirole at 5 min
Figure 1
Control (no inhibitor)	—	2.07 ± 0.17	−72.78 ± 4.83
β-ARK1 inhibitor	−2.71 ± 3.25	2.45 ± 0.27	−64.47 ± 3.42
Dynasore	−2.51 ± 2.49	2.35 ± 0.24	−62.99 ± 3.0
Figure 2
Control (no inhibitor)	—	2.55 ± 0.34	−68.27 ± 4.94
Neurotensin (10 nM)	—	3.63 ± 0.38	−65.5 ± 4.16
Neurotensin (5 nM)	—	3.15 ± 0.58	−61.65 ± 6.2
β-ARK1 inhibitor	−7.75 ± 3.53	1.8 ± 0.45	−68.21 ± 6.85
Gö6976	0.88 ± 3.0	1.38 ± 0.22	−64.54 ± 6.24
Dynasore	−6.79 ± 3.9	1.75 ± 0.15	−64.31 ± 6.35
Figure 3
Serotonin	—	2.53 ± 0.21	−64.02 ± 5.38
β-ARK1 inhibitor	−2.95 ± 1.94	2.23 ± 0.32	−73.68 ± 5.93
Gö6976	−9.04 ± 3.63	1.41 ± 0.28	−58.3 ± 2.75
Dynasore	−2.03 ± 2.63	2.59 ± 0.3	−62.26 ± 6.57

β-ARK1 inhibitor, methyl 5-[2-(5-nitro-2-furyl)vinyl]-2-furoate; DA, dopamine; FR, firing rate; Gö6976 (5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbozole-12-propanenitrile); VTA, ventral tegmental area.